2019 Nova Law Review Symposium

First Do No Harm: A Patient-Driven Approach to Navigating the Health Law, Intellectual Property, and Technology Maze

Friday, October 11, 2019 | 9:00 a.m. - 5:00 p.m.

NSU Shepard Broad College of Law | Panza Maurer Law Library, 3rd Floor

CLE Credit and Certification Credit information
The Florida Bar CLE Credits General 6.0 Ethics 2.0 Technology 2.0	The Florida Bar Certification Credits Health Law 6.0 Intellectual Property Law 2.0

Photo Album Audio Recording

Two of the fastest growing areas in the modern economy are health care and technology. In the race to provide innovations in health care and technology, however, the patient and caregiver are often left out of the conversation. Consequently, some technologies, intellectual property rules, health care options, and health policy decisions are replete with unintended consequences.

The Symposium presents an opportunity for academics, practitioners, health care providers, and students in a variety of legal, business, and technology fields to exchange ideas and explore emerging issues. Interdisciplinary presentations are encouraged.

Full Program & Biographies

Speakers (subject to change)
	Danna Khawam Nova Law Review \| Editor-in-Chief Vol. 44 Introductions
	Kathy Cerminara NSU Shepard Broad College of Law Professor of Law Moderator
PANELISTS & MODERATORS	What Would a Medical Data Information Commons Look Like, and how Would it Be Governed?
	Marielle S. Gross, MD, MBE Hecht-Levi Fellow, Johns Hopkins Berman Institute of Bioethics About Me, But Not for Me: The Ethical-Legal Gray Zone of Deidentified Health Data
	Melissa M. Goldstein, J.D. Associate Professor Department of Health Policy and Management, Milken Institute School of Public Health, George Washington University Redefining Sensitive Data
	Sharon Bassan, Ph.D. Jaharis Faculty Fellow in Health Law and Intellectual Property at the DePaul University College of Law Active Users? The Roles of Data Subjects in Managing Their Data
	Marilyn Uzdavines NSU Shepard Broad College of Law Professor of Law Moderator
	Patient Protection or Caveat Emptor? (Some) Risks Posed By High-Tech, Data-Driven Medicine
	Yaniv Heled, J.S.D., LL.M., LL.B. Associate Professor of Law of Law; Co-Director, Center for Intellectual Property Georgia State University College of Law Competition in Biological Pharmaceutical Markets
	Bethany Corbin, J.D., LL.M. Director of Master of Studies in Law, Wake Forest University FemTech: Societal, Ethical, and Privacy Implications of Digitizing the Female Body
	Jennifer Wagner, J.D., Ph.D. Geisinger Center for Translational Bioethics and Health Care Policy Precision Medicine and the FTC
	Robert Kain Shareholder, Kain Speilman PA Moderator
	Will Human Gene Editing Improve Health, Promote Eugenics, Or Both?
	Myrisha Lewis, J.D. William & Mary Law School The Coming Age of Gene Editing: Medical Promise, Regulation, and the Revival of Decades of Debate
	Seema Mohapatra, J.D. MPH Indiana University Robert H. McKinney Schooll of Law Regulating Human Germline Editing
	Samantha Zyontz, Ph.D. Research Fellow, Intellectual Property, Stanford Law School Running with (CRISPR) Scissors: Tool Adoption and Team Assembly
	Jonas Monast, J.D. C. Boyden Gray Distinguished Fellow, Assistant Professor and Director of the Center on Climate, Energy, Environment & Economics University of North Carolina School of Law Governing Extinction in the Era of Gene Editing
	Kathy Cerminara NSU Shepard Broad College of Law Professor of Law Moderator
	Question & Answer Panel
	Danna Khawam Nova Law Review \| Editor-in-Chief Vol. 44 Question & Answer Session
	Robert Scheppske Nova Law Review \| Goodwin Alumni Editor Question & Answer Session

A symposium issue based on the presentations at the conference will be published by the Nova Law Review.

Back to Events

First Do No Harm: A Patient-Driven Approach to Navigating the Health Law, Intellectual Property, and Technology Maze

What Would a Medical Data Information Commons Look Like, and how Would it Be Governed?

Patient Protection or Caveat Emptor? (Some) Risks Posed By High-Tech, Data-Driven Medicine

Will Human Gene Editing Improve Health, Promote Eugenics, Or Both?

Question & Answer Panel